fexofenadine has been researched along with Innate Inflammatory Response in 3 studies
fexofenadine: a second generation antihistamine; metabolite of the antihistaminic drug terfenadine; structure in first source; RN refers to HCl
fexofenadine : A piperidine-based anti-histamine compound.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fourteen atopic patients with mild-to-moderate asthma (forced expiratory volume in 1 second of 76%) completed a double-blind, randomized, crossover study consisting of 3-week treatment blocks of either fluticasone propionate-salmeterol, 250 microg twice daily, or fluticasone propionate alone, 250 microg twice daily, in conjunction with either fexofenadine, 180 mg once daily, or matched placebo." | 9.11 | Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma. ( Fardon, TC; Hodge, MR; Lee, DK; Lipworth, BJ, 2005) |
| "Fexofenadine treatment of sensitized mice prevented the development of airway hyperresponsiveness in both the primary sensitization and challenge, as well as in the adoptive transfer experiments." | 5.31 | Fexofenadine modulates T-cell function, preventing allergen-induced airway inflammation and hyperresponsiveness. ( Cui, ZH; Gelfand, EW; Joetham, A; Kanehiro, A; Takeda, K, 2002) |
| "Fourteen atopic patients with mild-to-moderate asthma (forced expiratory volume in 1 second of 76%) completed a double-blind, randomized, crossover study consisting of 3-week treatment blocks of either fluticasone propionate-salmeterol, 250 microg twice daily, or fluticasone propionate alone, 250 microg twice daily, in conjunction with either fexofenadine, 180 mg once daily, or matched placebo." | 5.11 | Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma. ( Fardon, TC; Hodge, MR; Lee, DK; Lipworth, BJ, 2005) |
| "Fexofenadine is a substrate of these transporters and it was previously shown that its clearance is reduced in the rat isolated perfused liver following treatment with E." | 1.36 | Pharmacokinetics of fexofenadine following LPS administration to rats. ( Davey, AK; Gerber, JP; Jaisue, S, 2010) |
| "Fexofenadine treatment of sensitized mice prevented the development of airway hyperresponsiveness in both the primary sensitization and challenge, as well as in the adoptive transfer experiments." | 1.31 | Fexofenadine modulates T-cell function, preventing allergen-induced airway inflammation and hyperresponsiveness. ( Cui, ZH; Gelfand, EW; Joetham, A; Kanehiro, A; Takeda, K, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jaisue, S | 1 |
| Gerber, JP | 1 |
| Davey, AK | 1 |
| Gelfand, EW | 1 |
| Cui, ZH | 1 |
| Takeda, K | 1 |
| Kanehiro, A | 1 |
| Joetham, A | 1 |
| Fardon, TC | 1 |
| Lee, DK | 1 |
| Hodge, MR | 1 |
| Lipworth, BJ | 1 |
1 trial available for fexofenadine and Innate Inflammatory Response
| Article | Year |
|---|---|
Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma.
Topics: Adenosine Monophosphate; Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Alb | 2005 |
2 other studies available for fexofenadine and Innate Inflammatory Response
| Article | Year |
|---|---|
Pharmacokinetics of fexofenadine following LPS administration to rats.
Topics: Administration, Oral; Animals; Anti-Allergic Agents; Biological Availability; Inflammation; Injectio | 2010 |
Fexofenadine modulates T-cell function, preventing allergen-induced airway inflammation and hyperresponsiveness.
Topics: Adoptive Transfer; Allergens; Animals; Anti-Allergic Agents; Bronchial Hyperreactivity; Bronchoalveo | 2002 |